• Disease
  • Multiple
  • Multiple Endocrine
  • Izumi Komoto

    Prominent publications by Izumi Komoto

    KOL Index score: 15472

    Purpose: Patients with pancreatic neuroendocrine neoplasm grade-3 (PanNEN-G3) show variable responses to platinum-based chemotherapy. Recent studies indicated that PanNEN-G3 includes well-differentiated neuroendocrine tumor with G3 (NET-G3). Here, we examined the clinicopathologic and molecular features of PanNEN-G3 and assessed the responsiveness to chemotherapy and survival.Experimental Design: A total of 100 patients with PanNEN-G3 were collected from 31 institutions, and after ...

    Also Ranks for: Rb Loss |  pancreatic neuroendocrine |  kras mutation |  net g3 |  response chemotherapy
    KOL Index score: 13781

    AIM: To search for the optimal surgery for gastrinoma and duodenopancreatic neuroendocrine tumors in patients with multiple endocrine neoplasia type 1.

    METHODS: Sixteen patients with genetically confirmed multiple endocrine neoplasia type 1 (MEN 1) and Zollinger-Ellison syndrome (ZES) underwent resection of both gastrinomas and duodenopancreatic neuroendocrine tumors (NETs) between 1991 and 2009. For localization of gastrinoma, selective arterial secretagogue injection test (SASI test) ...

    Also Ranks for: Multiple Endocrine |  type 1 |  gastrinoma patients |  sasi test |  biochemical cure
    KOL Index score: 11366


    Although neuroendocrine tumors (NETs) are rare, the number of patients with NET is increasing. However, in Japan, there have been no epidemiological studies on NET since 2005; thus, the prevalence of NET remains unknown.Methods

    We reported the epidemiology of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) [pancreatic neuroendocrine tumors (PNETs) and gastrointestinal neuroendocrine tumors (GI-NETs)] in Japan in 2005. Here, we conducted the second nationwide survey on ...

    Also Ranks for: Nationwide Survey |  gastrointestinal neuroendocrine |  epidemiological trends |  patients net |  distant metastasis
    KOL Index score: 10703

    Aims/hypothesisG protein-coupled receptor 40 (GPR40) is abundantly expressed in pancreatic beta cells in rodents, where it facilitates glucose-induced insulin secretion in response to mid- to long-chain fatty acids in vitro. However, GPR40 gene expression in humans has not been fully investigated, and little is known about the physiological and pathophysiological roles of GPR40 in humans. The aim of this study, therefore, was to examine GPR40 expression and its clinical implications in ...

    Also Ranks for: Gpr40 Expression |  insulin secretion |  pancreatic beta cells |  islet cell |  neoplastic humans
    KOL Index score: 9995


    The current study evaluated efficacy of

    the intravenous calcium injection test as a new diagnostic approach to

    clarify the existence of gastrinoma, which often goes undetected with

    routine testing. Twenty-six patients with hypergastrinemia were

    studied. For the calcium injection test, blood samples were taken from

    12 patients with hypergastrinemia (HG), and three healthy volunteers,

    and one patient with nonfunctioning endocrine tumor in the pancreas

    (control). We compared ...

    Also Ranks for: Differential Diagnosis |  calcium injection |  secretin test |  zes patients |  blood samples
    KOL Index score: 8933

    BackgroundThere have been few epidemiological studies on gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in Japan.MethodsWe examined the epidemiology of GEP-NETs [pancreatic endocrine tumors (PETs) and gastrointestinal neuroendocrine tumors (GI-NETs)] in Japan in 2005 using a nationwide stratified random sampling method.ResultsA total of 2,845 individuals received treatment for PETs. Prevalence was estimated as 2.23/100,000 with an annual onset incidence of 1.01/100,000. ...

    Also Ranks for: Neuroendocrine Tumors |  ginets japan |  tumor size |  distant metastases |  annual onset incidence
    KOL Index score: 8113

    More than 50% of patients with multiple endocrine neoplasia type 1 (MEN1) develop gastroenteropancreatic neuroendocrine tumors (GEPNETs), and insulinoma is the second most common functioning GEPNET. Compared to other functioning and nonfunctioning GEPNETs in MEN1, insulinoma is considered to develop at a younger age. To clarify the clinical features of insulinoma developed in Japanese patients with MEN1, a recently constructed database of Japanese MEN1 patients was analyzed. Among 560 ...

    Also Ranks for: Multiple Endocrine |  men1 patients |  type 1 |  age diagnosis |  pancreatic neoplasms
    KOL Index score: 7552

    BackgroundThe worldwide prevalence and incidence of neuroendocrine neoplasms (NEN) have been increasing recently, although few studies have analyzed data on the current situation of NENs in Japan. Here, the Japan Neuroendocrine Tumor Society (JNETS) planned to investigate the recent incidence and distribution of these tumors using data from the national cancer registry started in 2016. This study examined the incidence and distribution of primary sites as well as rate of advanced disease ...

    Also Ranks for: Neuroendocrine Neoplasms |  japan nens |  tumors pancreatic |  primary sites |  cancer registry
    KOL Index score: 7520

    Ghrelin is a 28-amino acid peptide that regulates GH release together with GHRH and somatostatin. The expression of ghrelin has been detected in the stomach, small intestine, hypothalamus, pituitary gland, kidney, placenta, and testis. Recently it was reported that ghrelin is present in pancreatic alpha-cells and that it stimulates insulin secretion. In this study, we examined the ghrelin expression in two cases of glucagonoma and two cases of insulinoma by Northern blot analysis and ...

    Also Ranks for: Ghrelin Expression |  multiple endocrine |  islet cell |  insulin secretion |  pituitary gland
    KOL Index score: 7451

    BackgroundThe role of surgery in pancreatic neuroendocrine neoplasm grade 3 (pNEN-G3) treatment remains unclear. We aimed to clarify the role of surgery for pNEN-G3, which has recently been reclassified as pancreatic neuroendocrine tumor-G3 (pNET-G3) and pancreatic neuroendocrine carcinoma-G3 (pNEC-G3), with and without metastases, respectively.MethodsWe analyzed a subgroup of patients from the Japanese pancreatic NEC study, a Japanese multicenter case-series study of pNEN-G3. ...

    Also Ranks for: Pancreatic Neuroendocrine |  carcinoma g3 |  aged neoplasm |  surgical procedures |  patients pnet
    KOL Index score: 7308

    BackgroundWe conducted a nationwide survey to estimate the incidence of neuroendocrine gastrointestinal tumors (NETs) newly diagnosed in Japan from 2002 through 2004.MethodsData on 1541 patients, 514 pancreatic endocrine tumors (PETs) and 1027 gastrointestinal carcinoids (GICs), were collected and analyzed.ResultsNonfunctioning tumors (NF-PET) constituted 47.7% of PETs. Next in frequency were insulinoma (31.7%) and gastrinoma (8.6%). Malignancy was frequent in NF-PETs (46.1%) and ...

    Also Ranks for: Nationwide Survey |  pets 74 |  nets japan |  neuroendocrine tumors |  multiple endocrine
    KOL Index score: 7014

    Background Lanreotide is a long-acting somatostatin analog with demonstrated efficacy against enteropancreatic neuroendocrine tumor (NET) in the phase III (CLARINET) study. Materials and Methods In this single-arm study, Japanese patients with grade (G) 1/G2 NET received lanreotide (120 mg/4 weeks) for 48 weeks. Those who completed the study were enrolled in a long-term extension study. The primary endpoint was the clinical benefit rate (CBR) defined as a complete response, partial ...

    Also Ranks for: Japanese Patients |  neuroendocrine tumors |  lanreotide autogel |  neoplasms peptides |  cbr orr


    Izumi Komoto: Influence Statistics

    Sample of concepts for which Izumi Komoto is among the top experts in the world.
    Concept World rank
    diagnosis pdnets #2
    revealed gastrinoma #2
    japan neuroendocrine #2
    progress treatment strategy #2
    nens esophagus #2
    japan nen #2
    multinodular brunners glands #2
    12037 pg #2
    curative surgery gastrinoma #2
    duodenopancreatic region #2
    gastrinoma development #2
    ellison syndrome increase #2
    misdiagnosis consensus #2
    gepnen japan #2
    functioning pdnets #2
    liver sasi test #2
    interventional zollinger gastrinoma #2
    extreme acid hypersecretion #2
    pdnet functioning pdnets #2
    treatment pdnet #2
    performed sasi #2
    multiple pdnet #2
    nen gepnen #2
    liver sasi #2
    distribution gepnen #2
    distribution gep #2
    net functioning #2
    gastrinoma accompanied #2
    gepnen population data #2
    conventional ulcer operations #2
    interventional zollinger #2
    pdnet neoplasia #2
    vagotomy distal gastrectomies #2
    ileum appendix #2
    nens japan #2
    japan gepnen #2
    gastrinoma duodenum #2
    pdnets textbook #2
    grastrinomas #2
    sasi test #2
    general clinician delay #2
    japan nens #2
    insulinoma japan #2
    jejunal peptic ulcers #2

    Key People For Multiple Endocrine

    Top KOLs in the world
    Stephen J Marx∘∘
    multiple endocrine men1 gene primary hyperparathyroidism
    Samuel A Wells
    multiple endocrine parathyroid glands carcinoembryonic antigen
    Rajesh V Thakker
    multiple endocrine neoplasia type mutational analysis
    Britt M Skogseid
    multiple endocrine men1 gene neoplasia type
    Maria Luisa Brandi
    multiple endocrine estrogen receptor postmenopausal women
    Bruce Anthony John Ponder
    breast cancer multiple endocrine neoplasia type

    Izumi Komoto:Expert Impact

    Concepts for whichIzumi Komotohas direct influence:Multiple endocrine,  Gastric carcinoma,  Rb loss,  Neuroendocrine tumors,  Human pancreas,  Ghrelin expression,  Primary hepatic gastrinoma,  Japanese patients.

    Izumi Komoto:KOL impact

    Concepts related to the work of other authors for whichfor which Izumi Komoto has influence:Neuroendocrine tumors,  Multiple endocrine,  Insulin secretion,  Lymph node metastasis,  Esophageal cancer,  Chemokine receptors,  Neoplasia type.



    Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

    Kansai Electric Power Medical Research Institute, Osaka 553-0003, Japan | Department of Surgery, Kansai Electric Power Hospital, Osaka 553-0003, Japan;, i-komoto@mx.bw.dream.jp, (I.K.);, imamura.masayuki@c4.kepco.co.jp, (M.I.) | Department of Surgery